- Open Access
Reduction of voltage gated sodium channel protein in DRG by vector mediated miRNA reduces pain in rats with painful diabetic neuropathy
Molecular Pain volume 8, Article number: 17 (2012)
Painful neuropathy is a common complication of diabetes. Previous studies have identified significant increases in the amount of voltage gated sodium channel isoforms NaV1.7 and NaV1.3 protein in the dorsal root ganglia (DRG) of rats with streptozotocin (STZ)-induced diabetes. We found that gene transfer-mediated release of the inhibitory neurotransmitters enkephalin or gamma amino butyric acid (GABA) from DRG neurons in diabetic animals reduced pain-related behaviors coincident with a reduction in NaV1.7 protein levels in DRG in vivo. To further evaluate the role of NaVα subunit levels in DRG in the pathogenesis of pain in diabetic neuropathy, we constructed a non-replicating herpes simplex virus (HSV)-based vector expressing a microRNA (miRNA) against NaVα subunits.
Subcutaneous inoculation of the miRNA-expressing HSV vector into the feet of diabetic rats to transduce DRG resulted in a reduction in NaVα subunit levels in DRG neurons, coincident with a reduction in cold allodynia, thermal hyperalgesia and mechanical hyperalgesia.
These data support the role of increased NaVα protein in DRG in the pathogenesis of pain in diabetic neuropathy, and provide a proof-of-principle demonstration for the development of a novel therapy that could be used to treat intractable pain in patients with diabetic neuropathy.
Pain is a common complication of diabetic neuropathy that, despite substantial advances in understanding of pathophysiology, remains relatively refractory to treatment with available agents . In rats with streptozotocin (STZ) induced diabetes and painful neuropathy, an increase in the alpha (pore-forming) subunit of voltage gated sodium channel isoform 1.7 (NaV1.7) in primary sensory afferent neurons of the dorsal root ganglia (DRG) has been reported , a change that correlates with increased amplitude and negative shift of the activation of tetrodotoxin (TTX)-sensitive current in those neurons. A potential pathogenic role for NaV1.7 in the development of pain in this syndrome is supported by the observation that gain of function mutations in NaV1.7 cause inherited spontaneous neuropathic pain syndromes primary erythermalgia [3, 4] and paroxysmal extreme pain disorder .
In previous studies we have constructed a series of herpes simplex virus (HSV)-based gene transfer vectors that effectively transduce DRG in vivo from skin inoculation, and have used these vectors to express inhibitory neurotransmitters [6–8] or neurotrophic factors [9–11]. In order to explicitly test the role of increased levels of NaV in DRG in the pathogenesis of pain in PDN, we constructed a non-replicating herpes simplex virus (HSV)-based vector to reduce NaVα protein in DRG, and compared the effect of NaVα subunit knockdown on pain-related behaviors in PDN with the effect in a standard model of inflammatory pain.
Results and discussion
The data reported here demonstrate that, 1) an HSV vector expressing an miRNA against voltage gated NaV alpha subunits reduces expression of NaVs in DRG in vivo; 2) normalization of NaV1.7 levels in STZ-diabetic rats achieved by the miNaV-expressing vector substantially reduced pain related behaviors in the STZ rat model of painful diabetic neuropathy; but in comparison, 3) the reduction in expression achieved by the miNaV-expressing vector produced only a modest reduction in inflammatory pain (flinching) in the acute and delayed phases of the formalin test.
Knockdown of NaVα channels
A series of miRNA sequences targeting common rat NaV α subunits were constructed and inserted into the nonreplicating HSV recombinant UL41E1G6-M . The resulting series of vectors were used to transfect primary DRG neurons in culture at a multiplicity of infection (MOI) of 1 for 2 hours, and 48 hours later the amount of NaV1.7 mRNA determined by RT-PCR. The most effective vector construct, designated QHmiNaV (Figure 1) was used in the experiments reported. Control vector QHmiSc was identical to QHmiNaV but contained a scrambled sequence in place of NaV miRNA sequence.
The sequence inserted into QHmiNaV was a perfect match for NaV1.7 and for NaV1.3, but an imperfect match for other NaVs (Figure 2a). We examined the effect of QHmiNaV infection on expression of DRG NaV isoforms NaV 1.3, 1.6, 1.7 and 1.8 by examining isoform- specific mRNA levels 3 days after infection of primary DRG neurons in culture at an MOI of 1. Infection with QHmiNaV produced a substantial reduction in the levels of NaV1.6 and 1.7 mRNAs, and about a 50% reduction in the amount of NaV1.8 mRNA in infected DRG neurons (Figure 2b). Infection with QHmiSc at an MOI of 1 resulted in no change in NaV α subunit mRNA levels. The change in NaV protein levels assessed using a well characterized anti-NaV1.7 antibody, lagged several days behind the reduction in RNA reaching 80% of basal levels at 10 days after infection reflecting the half-life of already synthesized protein (data not shown).
NaVs are crucial determinants of neuronal excitability [13, 14], and the NaV isoforms NaV1.3, NaV1.6, NaV1.7, NaV1.8, and NaV1.9 are all expressed in DRG neurons. Transgenic mouse and knockdown studies have principally implicated the isoforms NaV1.3, NaV1.8 and NaV1.9 in inflammatory and nerve injury related pain [15–19]. NaV1.8-null mutant mice lack slowly inactivating sodium currents and unable to sense cold pain or mechanical pressure . These animals also exhibit deficits in inflammatory pain behavior, yet they respond normally to heat. In carrageenan and complete Freund's adjuvant-induced hyperalgesia there is an increase in NaV1.8 and NaV1.9 currents [21, 22] and an increase in the expression of NaV1.8 in DRG has been reported . Knockdown of NaV1.8 by intrathecal delivery of antisense oligonucleotide against NaV1.8 reduces CFA-induced hyperalgesia [24, 25].
QHmiNaV reverses the increase in NaV1.7 caused by diabetes
There is a significant increase in NaV1.7 protein in DRG of rats rendered diabetic by injection of streptozotocin (STZ) [2, 6] that correlates with thermal hyperalgesia, mechanical hyperalgesia and cold allodynia, characteristic of painful diabetic neuropathy in these animals. Subcutaneous inoculation of HSV vectors results in transduction of ipsilateral DRG . Two weeks after the onset of diabetes 30 μl containing either 3 × 109 pfu of QHmiNaV or QHmiSc was injected into the plantar surface of both hind feet. Two weeks after the vector inoculation (4 weeks after onset of diabetes), the amount of NaV1.7 protein was significantly increased in the diabetic animals (Figure 3a) and in diabetic animals inoculated with the QHmiSc, but there was a substantial reduction in the amount of NaV1.7 in diabetic animals inoculated with QHmiNaV (Figure 3a). QHmiNaV brought the amount of NaV1.7 protein in diabetic animals back to near normal but not completely normal levels. By in situ hybridization the reduction in NaV1.7 RNA expression was found to be widely distributed in neurons in the DRG, and the in situ study suggested a reduction of about 50% in the amount of NaV1.7 mRNA in the DRG compared to diabetic animals (Figure 3b). To separately estimate the number of DRG neurons transfected after footpad inoculation of the vector, we performed in situ hybridization for the reporter gene GFP which revealed 40-50% of the neurons in individual sections with GFP reporter RNA (Additional File 1).
HSV-mediated knockdown of NaV ameliorates pain-related behaviors in diabetic animals
Diabetic rats demonstrate thermal hyperalgesia, cold allodynia and mechanical hyperalgesia [6, 8]; all of these signs of neuropathic pain were improved by inoculation with QHmiNaV. Thermal hyperalgesia was manifested by a decrease in withdrawal latency in response to noxious thermal stimuli (control 8.62 ± 1.3 sec; diabetic 4.89 ± 0.5 sec; p < 0.005). Two weeks after inoculation (4 weeks after diabetes) animals inoculated with QHmiNaV showed a statistically significant increase in thermal latency (QHmiNaV 7.92 ± 0.7 sec compared to diabetic; p < 0.005) and control vector QHmiSc inoculated diabetic animals (QHmiSc 5.5 ± 0.8 sec; p < 0.01 compared to QHmiNaV) (Figure 4). Cold allodynia was manifested by a decreased latency to withdraw from a cold acetone spray in diabetic compared to control animals (diabetic 3.1 ± 0.6 sec; control 18.1 ± 3.9 sec p < 0.001). Diabetic animals inoculated with QHmiNaV showed an increased latency to withdraw from this stimulus compared to diabetic control vector inoculated animals (QHmiNaV 16.9 ± 2.1 sec; QHmiSc 6.2 ± 2.1 sec; p < 0.001). Mechanical hyperalgesia was tested using the method described by Randall and Sellito. Inoculation of QHmiNaV significantly increased the pressure threshold (QHmiNaV 105.9 ± 4.9 gm) compared to diabetic animals (55.5 ± 3.4 gm; p < 0.001) and QHmiSc-inoculated animals (62.7 ± 2.9 gm; p < 0.001) measured 4 week after inoculation (Figure 4).
In STZ-induced PDN there is a marked increase in NaV 1.7 protein in DRG [2, 27, 28], an increase that is mediated by phosphorylation of PKC [6, 8]. While the pathogenesis of pain in PDN is complex and many molecular entities may be involved , in studies using HSV-based vectors to transfer genes to the DRG in vivo, we observed that vector-mediated release of gamma aminobutyric acid (GABA) from the DRG of diabetic animals results in a reduction in pain-related behaviors, coincident with a reduction in NaV1.7 protein in the DRG achieved through activation of presynaptic GABAB receptors . We also found that gene transfer-mediated release of the inhibitory neurotransmitter enkephalin resulted in a greater reduction of neuropathic pain-related behaviors in animals with neuropathic pain resulting from diabetic neuropathy  compared to animals with neuropathic pain resulting from spinal nerve ligation , and that continuous activation of presynaptic delta opioid receptors by vector-produced enkephalin in the diabetic animals also resulted in a reduction in the amount of NaV1.7 protein in diabetic DRG in vivo.
These results support the interpretation that increased NaV1.7 protein in DRG plays in the pathogenesis of pain in this model of PDN. The potential role of NaV1.7 in the pathogenesis of pain in PDN is also supported by the observation that gain-of-function mutations in SCN9A, the gene encoding NaV1.7 result in the spontaneous pain syndromes primary erythermalgia and paroxysmal extreme pain disorder [30, 31], and that loss of function mutations in NaV1.7 result in an inherited channelopathy characterized by total insensitivity to pain .
NaV1.7 is the principal TTX-sensitive channel in small DRG neurons, and is responsible for almost half of the current in those neurons, and the increase in NaV1.7 protein is accompanied by an increase in TTX-sensitive current in those cells . There is also an increase in TTX-resistant currents in diabetic rats [27, 33] that is likely related to modulation of individual channel properties related to phosphorylation . Waxman and colleagues have suggested that NaV1.7, which opens in response to slow ramp depolarization may serve to "set the gain" for repetitive firing . If that is the case, an increase in the number of NaV1.7 channels can serve to lower the gain allowing for altered thresholds and spontaneous pain. There is one early published report in which an increase in NaV1.7 in the DRG of STZ-diabetic rats was not observed using immunocytochemistry , but several subsequent studies using Western blot found an increase in NaV1.7 [2, 6, 8]. The results of the current study provide support for the interpretation that an increase in the amount of NaV1.7 plays a role in the pathogenesis of pain in this model of PDN.
QHmiNaV reduces NaV1.7 and 1.8 in normal animals, but produces only a modest reduction in formalin-induced flinching
Twenty one days after subcutaneous inoculation of QHmiNaV into the hind paw of normal rats, the amount of NaV1.7 was reduced by 50% and the amount of NaV1.8 by 40% compared to QHmiSc-inoculated animals (Figure 5a and 5b). Animals inoculated with QHmiNaV showed a small but statistically significant reduction in formalin - induced flinching behavior in the delayed phase of the formalin test (Figure 5c).
There is always a possibility in experiments of this type that the directed siRNA may knock down the expression of proteins unrelated to the target gene. While this is an important consideration, the prior evidence indicating a role for NaV in the pathogenesis of pain, coupled with the reduction in pain when NaV expression is reduced to just that we are looking at on-target effects of NaV knockdown. We do not interpret our observation that vector-mediated knock down of NaV resulted in only a modest reduction in spontaneous pain in the formalin test to indicate that NaV1.7 may not important in inflammatory pain. Yeomans and coworkers reported previously that a related HSV vector engineered to express an NaV1.7 antisense construct reduced inflammatory hyperalgesia resulting from injection of complete Freund's adjuvant , and Woods and colleagues reported that mice with double knockouts for both NaV1.7 and NaV1.8 show a substantial reduction in pain related behavior in the delayed phase of the formalin test, in contrast to NaV1.8 knockouts that demonstrate a normal behavior in the delayed phase . The results of the current study however do suggest that a 40 to 50% reduction from normal amounts in the amount of NaV1.7 and NaV1.8 in the DRG does not impair the ability of nociceptors to respond in a functionally meaningful manner to the acute inflammatory stimulus.
Woods and colleagues also reported that the NaV1.7 and NaV1.8 double knockouts demonstrate no impairment in the development of pain in response to nerve injury (L5 spinal nerve ligation) . Those results, as well as other experiments that demonstrate different changes in NaV isoform levels in different models of neuropathic pain  are not incompatible with the current study. Rather, they point to what may be important differences in the pathogenesis of different forms of neuropathic pain, in particular the role played by the substantial increase in NaV1.7 protein in PDN.
HSV is a vector that is uniquely suited to deliver genes into DRG neurons in vivo. While much of the previously published work using HSV based vectors has characterized the delivery, expression and biological properties of peptides or proteins expressed from these vectors that are released from transduced neurons [37–39], the results of the current study extend the utility of these vectors to the production of interfering RNAs acting intracellularly. A nonreplicating HSV vector expressing preproenkephalin has been brought to human trial . It is possible that a miRNA-expressing HSV vector could be used in a similar fashion to treat patients with intractable persistent pain from diabetic neuropathy.
To construct miRNAs targeting rat NaV α subunits present in DRG, we constructed a vector to express a miRNA targeted to a common sequence of NaV1 α subunits. A3 top strand oligo 5'-TGC TGG GAA CAA GCA GAT CAT GCT GTG TTT TGG CCA CTG ACA CAG CAT GCT GCT TGT TCC-3' A3 bottom strand oligo 5'-CCT GGG AAC AAG CAG CAT GCT GTG TCA GTC AGT GGC CAA AAC ACA GCA TGA TCT GCT TGT TCC C -3'. Equal amounts of the single-stranded oligos were annealed to generate a double-stranded oligo that ligated with the linearized plasmid pcDNATM6.2-GW/EmGFP-miRNA (Invitrogen), amplified using the following PCR primers with mulI site at 5' end an ECORI site at 3' end, forward primer: 5'-ACG CGT GCT AGT TAA GCT ATC AAC AAG-3' and reverse primer: 5'-GAA TTC GTA CAA GAA AGC TGG GTC TAG-3'. The PCR fragment was extracted by Qia-quick Gel Extraction Kit (Qiagen, Valencia, CA), and 3 ul of the gel-extracted PCR fragment ligated into PGEM-T vector system I kit (Promega; Madison, WI) for expansion. The resulting PCR fragment was cut out from PGEM-T plasmid by MluI and EcoRI, purified by gel electrophoresis and cloned into MluI and EcoRI -cut shuttle plasmid SASB3-M4. The shuttle plasmid containing the insert was then cotransfected with the non-replicating HSV vector UL41E1G6-M in complementing 7B cells, and and a single green virus isolated through serial dilution. Every round of purification was confirmed by sequencing, and the construct designated QHmiNaV. A control vector identical to QHmiNaV, but containing a scrambled-miRNA sequence in place of NaV α subunit miRNA was constructed and designated QHmiSc.
Diabetic animal model
Following an overnight fast, male Sprague Dawley rats weighing 225-250 gms were injected with streptozotocin (STZ, Sigma, USA) 50 mg/kg, i.p. in citrate buffer (pH 5.5). The development of diabetes was confirmed by measuring blood glucose and animals with blood glucose level ≥ 300 mg/dl included as diabetic. There were 8-10 animals per group in all these studies.
Diabetic animals were inoculated subcutaneously in the footpad of the both hind paws with 30 μl containing 1 × 107 plaque forming units with either QHmiNaV or the control vector QHmiSc 2 weeks after the onset diabetes. Control animals or diabetic only animals were injected PBS in the footpad. A separate cohort of diabetic animals were inoculated with the vector and euthanized 2 weeks later to evaluate the efficacy of knockdown of RNA.
DRG neurons from 17-day-old rat embryos were cultured in Neurobasal Medium containing B27, Glutamax I, Albumax I, and penicillin/streptomycin (Gibco-BRL). After 7 days in culture, the cells were transfected with either QHmiNaV or QHmiSc at a multiplicity of infection (MOI) of 1 for 2 h. Fresh medium was replaced and collected 7 days later for determination of NaVs.
cDNA prepared from RNA isolated from DRG cells or rat L4-6 DRG were amplified using following primer sets: β-actin-F (5'-CAG TTC GCC ATG GAT GAC GAT ATC-3') and β-actin-R (5'-CAC GCT CGG TCA GGA TCT TCA TG-3') for β-actin, NaV1.6-F (5'-GAC AAT GAT GGT GGA GAC AGA CAC-3') and NaV1.6-R (5'-TTG GAG GCC ATC TTT CTG CAG-3') for NaV1.6. NaV1.7-F (5'-CCA TCA TGA ACG TGC TTC TCG TG-3') and NaV1.7-R (5'-CAA AGC AAA GAG CAG AGT GCG GAT C-3') for NaV1.7 and NaV1.8-F (5'-AAC AGC ACC GGC CAC TTC TTC-3') and NaV1.8-R (5'-CCG TTG CTG TTG GGC AGG TTG-3') for NaV1.8. All reactions involved initial denaturation at 94°C for 5 min followed by 28 cycles (for β-actin and NaV1.7) and 30 cycles (for NaV1.6 and NaV1.7) at 94°C for 30 sec, 68°C for 3 min, followed by 1 cycle at 68°C for 8 min using a GeneAmp PCR 2700 (Applied Biosystems, Foster City, CA).
Cells or pooled samples of L4-L6 DRG, were homogenized with lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 2% SDS, 10% glycerol, and 1:100 dilution of protease inhibitor mixture and phosphatase inhibitor mixture (Sigma), the homogenized cells and tissues were centrifuged at 10,000 × g for 10 min at 4°C, and the supernatant was stored at -80°C. An aliquot of supernatant was taken for protein estimation using a protein assay kit (Bio-Rad Laboratories, Hercules, CA). Total cell extract or total protein from DRG (20 μg of protein per lane) was separated by PAGE, transferred to an Immobilon-P membrane (0.45 μm; Millipore), blocked with 5% nonfat milk, and then incubated with the primary antibody. Primary antibodies included an antibody against NaV1.7, NaV1.8 (Chemicon) and anti-SP-19 (Sigma Aldrich) followed by horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG (1:5000; GE Healthcare) and visualized with ECL (Pierce) using a PC-based image analysis system (ChemiDoc XRS System; Bio-Rad Laboratories). The membranes were stripped and re-probed with mouse anti-β-actin (1: 2000; Sigma Aldrich) as a loading control. The intensity of each band was determined by quantitative chemiluminescence using a PC-based image analysis system (ChemiDoc XRS System, Bio-Rad Laboratories).
Rats were perfused with 4% paraformaldehyde, the L4-6 segment of DRG postfixed and cryoprotected, and 20 μm cryostat sections incubated with anti-GFP (Abcam). The secondary antibodies utilized were fluorescent anti-rabbit IgG Alexa Fluor 488 (1:2000; Molecular Probes, Eugene, OR). Images were captured using a Zeiss LSM 510 Meta confocal microscope.
In situ hybridization
Rats were anesthetized with ketamine/xylazine (100/10 mg/kg, IP) and perfused with 4% paraformaldehyde in 0.1 M phosphate buffer. L4-6 DRG were post-fixed and cryoprotected overnight at 4°C in 30% sucrose, and serial sections (10 μm) of DRG was cut onto slides and desiccated overnight. Sections from the different groups were processed for in situ hybridization for detection of NaV1.7 mRNA or GFP mRNA with incubation in 4% paraformaldehyde for 12 min and permeabilization with proteinase K for 6 min followed by hybridization with digoxigenin-labeled probes for NaV1.7 (5DigN/TTA CGT CGC CGT CCA GCT CG/3DigN) and GFP (5DigN/TTC TCA TCG TCA CCC TTT TCC T/3DigN) at 530 C overnight, followed by 1 hr blocking, 2 hrs of Anti-dig-AP antibody incubation and 1 hr color reaction with NBT/BCIP phosphate. The slides were then dehydrated and mounted in Permount. Digitized images of immunostained sections were captured with a Nikon E1000 microscope, and analyzed using a PC-based image analysis program (MCID, Imaging Research, Brock, ON, USA) by a technician blinded to the treatment group. All the cells in the cross-section of the DRG from three animals in each group were analyzed.
The latency to hind paw withdrawal from a thermal stimulus was determined by exposing the plantar surface of the hind paw to radiant heat using a modified Hargreaves thermal testing device . Rats were placed in individual enclosures on a glass plate maintained at 30°C, and after a 30 min habituation period the plantar surface of the paw exposed to a beam of radiant heat applied through the glass floor. Activation of the bulb simultaneously activated a timer, and both were immediately turned off by paw withdrawal or at the 20 sec cut-off time. Testing was performed by a blinded observer in triplicate at 5 min intervals.
Mechanical nociceptive threshold was assessed using an analgesimeter (Ugo Basile, Comerio, VA, Italy) as described by Randall and Selitto . A linearly increasing force was applied through a cone-shaped plastic tip with a diameter of 1 mm onto the dorsal surface of the hindpaw between the third and fourth metatarsals until the rat attempted to withdraw its paw or a pressure of 200 gms reached. The pain threshold determined as the mean of three consecutive stable values expressed in grams was determined by a blinded observer.
Animals were placed on a mesh floor 18 inches above the table and after 20 min of acclimatization, 0.1 ml of acetone was sprayed onto the plantar surface of the hind paw using a 1 cc syringe. The latency of the response, measured as the delay to a withdrawal response of either flinching or licking was used as a measure of cold allodynia, with a cut off limit at 40 sec. A total of 3 responses from each animal were assessed at 5 min intervals by a blinded observer.
To test inflammatory pain-related behavior, 21 days after inoculation of the vector into one hind paw, normal male Sprague Dawley rats 225-250 grams were acclimated to the test setup and injected with 50 μl of 5% formalin into the plantar surface of the ipsilateral hind paw. The number of flinches over the subsequent 60 minutes counted using an automated device .
The statistical significance of the difference between groups was determined by ANOVA (Systat 9) using Bonferroni's correction for the multiple post hoc analyses. All results are expressed as mean ± SEM. All the tissue culture experiments were repeated 3 times. The animal experiments, with 8-10 animals per group, were repeated twice.
Dorsal root ganglia
gamma amino butyric acid
Green fluorescence protein
herpes simplex virus
- NaV :
voltage gated sodium channel
painful diabetic neuropathy
Bril V, England J, Franklin GM, et al.: Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011, 76: 1758–65. 10.1212/WNL.0b013e3182166ebe
Hong S, Morrow TJ, Paulson PE, et al.: Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J Biol Chem 2004, 279: 29341–29350. 10.1074/jbc.M404167200
Yang Y, Wang Y, Li S, et al.: Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2004, 41: 171–174. 10.1136/jmg.2003.012153
Cummins TR, Dib-Hajj SD, Waxman SG: Electrophysiological properties of mutant Na v 1.7 sodium channels in a painful inherited neuropathy. J Neurosci 2004, 24: 8232–8236. 10.1523/JNEUROSCI.2695-04.2004
Fertleman CR, Baker MD, Parker KA, et al.: SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006, 52: 767–774. 10.1016/j.neuron.2006.10.006
Chattopadhyay M, Mata M, Fink DJ: Continuous delta opioid receptor activation reduces neuronal voltage gated sodium channel (Na V 1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci 2008, 28: 6652–6658. 10.1523/JNEUROSCI.5530-07.2008
Hao S, Mata M, Goins W, et al.: Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect. Pain 2003, 102: 135–142. 10.1016/s0304-3959(02)00346-9
Chattopadhyay M, Mata M, Fink DJ: Vector-mediated release of GABA attenuates pain-related behaviors and reduces Na(V)1.7 in DRG neurons. Eur J Pain 2011, 15: 913–920. 10.1016/j.ejpain.2011.03.007
Chattopadhyay M, Mata M, Goss J, et al.: Prolonged preservation of nerve function in diabetic neuropathy in mice by herpes simplex virus-mediated gene transfer. Diabetologia 2007, 50: 1550–1558. 10.1007/s00125-007-0702-4
Chattopadhyay M, Goss J, Wolfe D, et al.: Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain 2004, 127: 929–939. 10.1093/brain/awh103
Chattopadhyay M, Wolfe D, Huang S, et al.: In vivo gene therapy for pyridoxine- induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. Ann Neurol 2002, 51: 19–27. 10.1002/ana.10061
Peng X, Zhou Z, Hu J, et al.: Soluble Nogo receptor down-regulates expression of neuronal Nogo-A to enhance axonal regeneration. J Biol Chem 2010, 285: 2783–2795. 10.1074/jbc.M109.046425
Estacion M, Gasser A, Dib-Hajj SD, Waxman SG: A sodium channel mutation linked to epilepsy increases ramp and persistent current of Nav1.3 and induces hyperexcitability in hippocampal neurons. Exp Neurol 2010, 224: 362–368. 10.1016/j.expneurol.2010.04.012
Dib-Hajj SD, Cummins TR, Black JA, Waxman SG: Sodium channels in normal and pathological pain. Annu Rev Neurosci 2010, 33: 325–347. 10.1146/annurev-neuro-060909-153234
Liu M, Wood JN: The roles of sodium channels in nociception: implications for mechanisms of neuropathic pain. Pain Med 2011,12(Suppl 3):S93-S99.
McGaraughty S, Chu KL, Scanio MJ, et al.: A selective Nav1.8 sodium channel blocker, A-803467 [5-(4-chlorophenyl-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], attenuates spinal neuronal activity in neuropathic rats. J Pharmacol Exp Ther 2008, 324: 1204–1211.
Lai J, Gold MS, Kim CS, et al.: Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, Nav1.8. Pain 2002, 95: 143–152. 10.1016/S0304-3959(01)00391-8
Priest BT, Murphy BA, Lindia JA, et al.: Contribution of the tetrodotoxin-resistant voltage-gated sodium channel Nav1.9 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci USA 2005, 102: 9382–9387. 10.1073/pnas.0501549102
Roza C, Laird JM, Souslova V, et al.: The tetrodotoxin-resistant Na + channel Nav1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J Physiol 2003, 550: 921–926. 10.1113/jphysiol.2003.046110
Akopian AN, Souslova V, England S, et al.: The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 1999, 2: 541–548. 10.1038/9195
Waxman SG, Dib-Hajj S, Cummins TR, Black JA: Sodium channels and pain. Proc Natl Acad Sci USA 1999, 96: 7635–7639. 10.1073/pnas.96.14.7635
Gould HJ, England JD, Liu ZP, Levinson SR: Rapid sodium channel augmentation in response to inflammation induced by complete Freund's adjuvant. Brain Res 1998, 802: 69–74. 10.1016/S0006-8993(98)00568-X
Tanaka M, Cummins TR, Ishikawa K, et al.: SNS Na + channel expression increases in dorsal root ganglion neurons in the carrageenan inflammatory pain model. Neuroreport 1998, 9: 967–972. 10.1097/00001756-199804200-00003
Porreca F, Lai J, Bian D, et al.: A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc Natl Acad Sci USA 1999, 96: 7640–7644. 10.1073/pnas.96.14.7640
Yu YQ, Zhao F, Guan SM, Chen J: Antisense-mediated knockdown of Na(V)1.8, but not Na(V)1.9, generates inhibitory effects on complete Freund's adjuvant-induced inflammatory pain in rat. PLoS One 2011, 6: e19865. 10.1371/journal.pone.0019865
Chattopadhyay M, Walter C, Mata M, Fink DJ: Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons. Brain 2009, 132: 879–888.
Craner MJ, Klein JP, Renganathan M, et al.: Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann Neurol 2002, 52: 786–792. 10.1002/ana.10364
Hong S, Wiley JW: Altered expression and function of sodium channels in large DRG neurons and myelinated A-fibers in early diabetic neuropathy in the rat. Biochem Biophys Res Commun 2006, 339: 652–660. 10.1016/j.bbrc.2005.11.057
Bishnoi M, Bosgraaf CA, Abooj M, et al.: Streptozotocin-induced early thermal hyperalgesia is independent of glycemic state of rats: role of transient receptor potential vanilloid 1(TRPV1) and inflammatory mediators. Mol Pain 2011, 7: 52. 10.1186/1744-8069-7-52
Drenth JP, Waxman SG: Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest 2007, 117: 3603–3609. 10.1172/JCI33297
Dib-Hajj SD, Cummins TR, Black JA, Waxman SG: From genes to pain: Na v 1.7 and human pain disorders. Trends Neurosci 2007, 30: 555–563. 10.1016/j.tins.2007.08.004
Cox JJ, Reimann F, Nicholas AK, et al.: An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006, 444: 894–898. 10.1038/nature05413
Hirade M, Yasuda H, Omatsu-Kanbe M, et al.: Tetrodotoxin-resistant sodium channels of dorsal root ganglion neurons are readily activated in diabetic rats. Neuroscience 1999, 90: 933–939. 10.1016/S0306-4522(98)00486-2
Yeomans DC, Levinson SR, Peters MC, et al.: Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Nav1.7 sodium channels in primary afferents. Hum Gene Ther 2005, 16: 271–277. 10.1089/hum.2005.16.271
Nassar MA, Levato A, Stirling LC, Wood JN: Neuropathic pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8. Mol Pain 2005, 1: 24. 10.1186/1744-8069-1-24
Wang W, Gu J, Li YQ, Tao YX: Are voltage-gated sodium channels on the dorsal root ganglion involved in the development of neuropathic pain? Mol Pain 2011, 7: 16. 10.1186/1744-8069-7-16
Antunes Bras JM, Epstein AL, Bourgoin S, et al.: Herpes simplex virus 1-mediated transfer of preproenkephalin A in rat dorsal root ganglia. J Neurochem 1998, 70: 1299–1303.
Mata M, Glorioso JC, Fink DJ: Gene therapy: novel treatments for polyneuropathy and chronic pain. Curr Neurol Neurosci Rep 2004, 4: 1–2. 10.1007/s11910-004-0001-0
Glorioso JC, Fink DJ: Herpes vector-mediated gene transfer in the treatment of chronic pain. Mol Ther 2009, 17: 13–18. 10.1038/mt.2008.213
Fink DJ, Wechuck J, Mata M, et al.: Gene Therpay for Pain: Results of a Phase I Clinical Trial. Ann Neurol 2011, 70: 207–212. 10.1002/ana.22446
Hargreaves K, Dubner R, Brown F, et al.: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32: 77–88. 10.1016/0304-3959(88)90026-7
Randall LO, Sellito JJ: A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957, 111: 409–419.
Yaksh TL, Ozaki G, McCumber D, et al.: An automated flinch detecting system for use in the formalin nociceptive bioassay. J Appl Physiol 2001, 90: 2386–2402.
We acknowledge the assistance of Vikram Thakur Singh in vector propagation. This work was supported by grants from the Department of Veterans Affairs, the Juvenile Diabetes Research Foundation and the NIH (NS038850 and DK044935) to DJF and MM.
The authors declare that they have no competing interests.
MC researched data, wrote manuscript. ZZ researched data, reviewed/edited manuscript. SH researched data, reviewed/edited manuscript. MM reviewed/edited manuscript. DJF wrote manuscript. All authors read and approved the final manuscript.
About this article
Cite this article
Chattopadhyay, M., Zhou, Z., Hao, S. et al. Reduction of voltage gated sodium channel protein in DRG by vector mediated miRNA reduces pain in rats with painful diabetic neuropathy. Mol Pain 8, 17 (2012) doi:10.1186/1744-8069-8-17
- Gene therapy
- Sodium channel